Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 54, No. 4, 2008   

Free Abstract     Article (References)     Article (PDF 187 KB)     

Clinical Study

Phase II Trial of Neoadjuvant Cisplatin, 5-Fluorouracil and Interferon-Alpha in Operable Squamous Cell Carcinoma of the Esophagus
Shouki Bazarbashia, Mahmoud Abdelsalama, Tarek Aminb, Mazen El-Bassiounia, Hussein Soudya, Amr Elweshia, Hamed Alhusseinya, Khaled Rehmana, Muhammed Memona, Dahish Ajarima

aKing Faisal Cancer Center and
bDepartment of Surgery, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Address of Corresponding Author

Chemotherapy 2008;54:315-322 (DOI: 10.1159/000151353)


 goto top of page Key Words

  • Esophageal cancer
  • Interferon-alpha
  • Neoadjuvant chemotherapy

 goto top of page Abstract

Background: The combination of 5-fluorouracil (5-FU), cisplatin and interferon (IFN)-alpha was found to result in a high response rate in advanced esophageal squamous cell carcinoma (SCC). Methods: Resectable cases of esophageal SCC were treated with 3 cycles of chemotherapy consisting of cisplatin 70 mg/m2 i.v. on day 1, 5-FU 500 mg/m2/day i.v. as a continuous infusion on days 1-5 and IFN-alpha 4 million units/m2/day s.c. on days 1-5. Cycles were repeated every 21 days. Esophagectomy was performed 3-5 weeks after the 3rd cycle of chemotherapy. Results: Thirty patients were enrolled in the trial. Toxic death was observed in 1 patient because of esophageal perforation. Pathologically, complete response was observed in 4 of 23 patients who had esophagectomy. At a median follow-up period of 21.4 months, median progression-free survival was 11.5 months and median overall survival was 26.3 months. Conclusion: This regimen has substantial activity in localized SCC of the esophagus with encouraging survival duration.

Copyright © 2008 S. Karger AG, Basel


 goto top of page Author Contacts

Mahmoud Abdelsalam, MD
Department of Medical Oncology, MBC 64
King Faisal Specialist Hospital and Research Center
PO Box 3354, Riyadh 11211 (Saudi Arabia)
Tel. +966 50 319 5076, Fax +966 144 00824, E-Mail mabdelsalam@kfshrc.edu.sa


 goto top of page Article Information

Received: September 25, 2007
Accepted after revision: April 22, 2008
Published online: August 14, 2008
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 6, Number of References : 28

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 18701820)
Download Citation



This journal is part of the fourth subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.





copyright  © 2010 S. Karger AG, Basel